23 June 2025: From today (23 June 2025), following approval by NICE, tirzepatide (Mounjaro®) will be available in the NHS for eligible patients who meet the strict, nationally-set, criteria. 

The current criteria is that patients are those with a BMI of 40 or higher, and with four or more of the qualifying comorbidities (hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes) will be eligible for assessment to identify their suitability for Mounjaro. Anyone not meeting these criteria will not be eligible for assessment in the first year of the drug being available. 

Please do not contact your GP; if you are eligible to be assessed you will be contacted over the coming months and invited to attend an appointment for assessment. Those with the greatest clinical need will be contacted first.

For more information about alternative local weight management services, visit the ICS website - Local Weight Management services - Staffordshire and Stoke-on-Trent, ICS. 

_____________________________________________________________________________________________ 

 Mission Statement

To put patients first offering a friendly supportive service

To deliver high quality, evidence-based care, and health promotion to our patients

To deliver a safe, effective, and responsive service

To provide the right care by the right person to each patient

To support our staff to grow

For an overview of general information about the Surgery, please click the link to our practice leaflet here. 

We want to hear from our patients at Alton Surgery. Your feedback is incredibly important and will help us to better deliver care services to all our patients.

If you have any comments about the care you have received or feedback on any of our services please do let us know. You can leave a review over on the NHS website here.

If you would like to make a complaint about our practice, please look at our procedure by clicking here.